Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials

References

• Hersh AL, Chambers HF, Maselli JH, et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168:1585–1591. doi:10.1001/archinte.168.21.235518663172
   PubMed Web of Science ®Google Scholar
• Garau J, Blasi F, Medina J, et al. Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study. BMC Infect Dis. 2015;15:78. doi:10.1186/s12879-015-0822-225879713
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10–e52. doi:10.1093/cid/ciu29624973422
   PubMed Web of Science ®Google Scholar
• Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect. 2012;65:128–134. doi:10.1016/j.jinf.2012.03.01322445732
   PubMed Web of Science ®Google Scholar
• Berger A, Oster G, Edelsberg J, Huang X, Weber DJ. Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect (Larchmt). 2013;14:304–312. doi:10.1089/sur.2012.10323590851
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–674. doi:10.1056/NEJMoa05535616914702
   PubMed Web of Science ®Google Scholar
• Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51:291–298. doi:10.1016/j.annemergmed.2007.11.04218222564
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Sader HS, Rhomberg PR, et al. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61.
   Web of Science ®Google Scholar
• McCurdy S, Lawrence L, Quintas M, et al. In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61.
   Web of Science ®Google Scholar
• Flamm RK, Rhomberg PR, Huband MD, et al. In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2016;60:6381–6385. doi:10.1128/AAC.00941-1627458220
   PubMed Web of Science ®Google Scholar
• Kingsley J, Mehra P, Lawrence LE, et al. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016;71:821–829. doi:10.1093/jac/dkv41126679243
   PubMed Web of Science ®Google Scholar
• O’Riordan W, McManus A, Teras J, et al. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018;67:657–666. doi:10.1093/cid/ciy16529518178
   PubMed Web of Science ®Google Scholar
• O’Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67–73. doi:10.1016/j.ijid.2014.10.00925448332
   PubMed Web of Science ®Google Scholar
• Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72:3471–3480. doi:10.1093/jac/dkx06629029278
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269, w264.19622511
   PubMed Web of Science ®Google Scholar
• Shuster JJ. Review: Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1. 0, Published 3/2011. Julian PT Higgins and Sally Green, Editors Wiley Online Library; 2011.
   Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d592822008217
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558. doi:10.1002/sim.118612111919
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi:10.1136/bmj.327.7420.89512958120
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–114. doi:10.1016/j.cct.2006.04.00416807131
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748.13655060
   PubMed Web of Science ®Google Scholar
• Remy JM, Tow-Keogh CA, McConnell TS, et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012;67:2814–2820. doi:10.1093/jac/dks30722875850
   PubMed Web of Science ®Google Scholar
• Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003;47:3260–3269. doi:10.1128/AAC.47.10.3260-3269.200314506039
   PubMed Web of Science ®Google Scholar